Immune-Onc Therapeutics is a private, clinical-stage cancer immunotherapy company developing novel myeloid checkpoint inhibitors targeting the LILRB family. Its lead clinical candidates are IO-108, an antagonist antibody targeting LILRB2 (ILT4) in Phase 1 for advanced solid tumors, and IO-202, a first-in-class antagonist antibody targeting LILRB4 (ILT3) in Phase 1 for AML, CMML and solid tumors. Additional pipeline assets include IO-106 (a LAIR1 antagonist), IO-312 (a bispecific targeting LILRB4) and multiple undisclosed programs. The company has collaborations and supply agreements with Regeneron and BeiGene to evaluate IO-108 and IO-202 in combination with anti-PD-1 therapies, and has received research grants from the NCI and CIRM. Headquartered in Palo Alto, California, Immune-Onc has also received strategic investment from The Leukemia & Lymphoma Society’s Therapy Acceleration Program (LLS TAP) and Wuxi Biologics HealthCare Venture. Management highlighted ongoing clinical milestones including dose escalation and expansion cohorts, FDA Fast Track designation for IO-202 in relapsed or refractory AML, and plans to further characterize biomarkers and mechanisms of action. Immune-Onc Therapeutics is a clinical-stage cancer immunotherapy company focused on developing novel biotherapeutics that target immunosuppressive myeloid checkpoints, specifically the LILRB family. Its lead program, IO-202, is a first-in-class antibody against LILRB4 (ILT3) being developed for acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and solid tumors; preclinical data indicate it can activate T-cell killing and enhance tumor cell detection. IO-202 entered a Phase I trial in September 2020 for AML with monocytic differentiation and CMML and received FDA Orphan Drug Designation for AML in October 2020. The company’s IO-108, an antagonist antibody targeting LILRB2 (ILT4), is in the IND‑enabling stage with plans to submit an IND in mid‑2021; other preclinical assets include IO-106 (anti-LAIR1) and multiple undisclosed programs. Immune-Onc has invested in proprietary models, assays and tools to interrogate myeloid biology and maintains strategic research collaborations with The University of Texas, Albert Einstein College of Medicine, and Memorial Sloan Kettering Cancer Center. Financially, the company has raised over $110 million since beginning operations in 2016 and is advancing its pipeline toward additional clinical milestones using newly raised capital. Immune-Onc Therapeutics is focused on the discovery and development of novel biologic treatments that target the tumor microenvironment and immune suppressive pathways. The company aims to translate unique scientific insights into first-in-class biotherapeutics and has a pipeline built on collaborations with The University of Texas, Albert Einstein College of Medicine, and Memorial Sloan Kettering Cancer Center. Headquartered in Palo Alto, California, Immune-Onc is preparing to move from translational research into the clinic. To support that transition it received Series B funding of more than $33 million to advance its pipeline programs. The company recently appointed Dr. Adrian Jubb as Chief Medical Officer and Dr. An Song as Senior Vice President of Development Sciences to lead clinical, regulatory, and translational development efforts. Immune-Onc describes a leadership team with deep drug-development experience drawn from leading biotechnology and pharmaceutical organizations. Immune-Onc Therapeutics is a Palo Alto, CA-based biopharmaceutical company co-founded in 2016 by Charlene Liao, Ph.D., and Guo-Liang Yu, Ph.D. The company focuses on discovering and developing novel therapeutic antibodies for cancer treatment. It applies scientific insights and drug-development expertise to advance immuno-oncology products. Immune-Onc plans to use its new financing to support discovery and development activities for its antibody programs. In June 2016 it raised $7M in a Series A to provide initial funding to advance its pipeline.

Total raised

$138M

Funding rounds

4

Latest round

Series B

Latest activity

Jan 2023